Introduction {#s1}
============

The largest organ of the body, the skin, allows exchange with the environment while shielding the organism from insults of mechanical, chemical, and infectious nature. In the skin, the epidermis acts as a mechanical barrier which prevents water loss and the entry of potentially harmful chemicals; in addition, through the interplay between keratinocytes in the epidermis and immune cells based mainly in the underlying dermis, the skin works as an immunological barrier actively defending the body from pathogens ([@bib46]; [@bib45]). Maintaining these barrier functions throughout life requires continuous regeneration of the epidermis and appropriately balanced immune responses. Dysregulation of the regenerative process can lead to a wide range of defects, from epidermal thickening to malignancies; and an imbalance in the skin's immune reactions can lead to recurrent infections, or inflammatory/allergic diseases such as psoriasis or atopic dermatitis.

The RAF/MEK/ERK signaling pathway plays an essential role in the epidermis. Downstream of the EGFR and RAS, it acts in hair follicle development and wound healing; its mild activation in Rasopathies, genetic diseases caused by activating mutations in the pathway, results in skin phenotypes ranging from thickening of palms and soles to the development of papillomas; and strong activation in keratinocytes results in tumorigenesis ([@bib33]; [@bib49]). In animal models, epidermis-restricted inducible activation of RAF or MEK causes massive cutaneous hyperplasia and reduced differentiation ([@bib35]). Consistently, RAF1 (also known as CRAF) and BRAF are essential for the development and progression of RAS-induced tumors although they fulfil different roles, with RAF1 preventing keratinocyte differentiation ([@bib21]) and BRAF promoting proliferation through MEK/ERK activation ([@bib34]). The requirement for MEK/ERK in epidermal proliferation has been independently assessed ([@bib35]; [@bib18]; [@bib51]; [@bib51]).

In line with their prominent roles in cell proliferation and tumorigenesis in a number of tissues, the components of the EGFR/RAS/RAF/MEK/ERK pathway are attractive targets for molecule-based therapy. Many inhibitory compounds have been developed that are currently in clinical trials or have reached the clinic. Reflecting the function of the pathway in skin, cutaneous toxicities are one of the main adverse effects of these therapies; they can be severe and lead to an interruption of the therapy or to its termination ([@bib4]; [@bib12]; [@bib19]). These adverse effects can be roughly classified as inflammatory reactions, elicited chiefly by blocking EGFR or MEK; and proliferative events, caused by multikinase inhibitors such as sorafenib or by more specific RAF inhibitors (vemurafenib, dabrafenib). Cutaneous inflammation induced by agents blocking EGFR (erlotinib or cetuximab) and by MEK inhibitors (selumetinib and trametinib) is characterized by papulopustular rash, pruritus, and suppurative folliculitis in ≥80% of the patients ([@bib12]). The effects of erlotinib and cetuximab are on-target, as recently demonstrated by two studies showing similar inflammatory phenotypes in mice with epidermis-restricted EGFR ablation ([@bib42]; [@bib40]).

Skin rashes and pruritus are also observed in patients treated with inhibitors targeting RAF. Up to half of the cutaneous reactions induced by these compounds, however, consist of anomalous epidermal proliferation events ranging from different forms of keratosis to the development of drug-induced papillomas, keratoacanthomas, and squamous cell carcinomas (4--30% depending on the study and the inhibitors used) ([@bib2]). These side effects are mechanism-based and rely on the paradoxical activation of MEK/ERK promoted by the inhibitors in cultured cells, animal models, and patients ([@bib50]; [@bib29]). Consistent with this, combination treatment (RAF plus MEK inhibitors) reduces cutaneous toxicity ([@bib24]; [@bib43]).

In contrast to RAF inhibitor treatment, inducible epidermis-restricted ablation of BRAF and RAF1 causes the rapid regression of RAS-driven tumors without apparent cutaneous toxicity ([@bib34]). Here, we systematically test the effect of compound BRAF/RAF1 ablation in epidermis and show that it gives rise to a progressive disease strongly resembling human atopic dermatitis. Mechanistically, the disease relies on the combination of reduced ERK and increased stress kinase activation, leading to chemokine/cytokine overproduction and chronic, systemic inflammation.

Results {#s2}
=======

Epidermal BRAF and RAF1 are essential to prevent local and systemic inflammation {#s2-1}
--------------------------------------------------------------------------------

BRAF and RAF1 were ablated in the epidermis by introducing the *Krt5-Cre* transgene ([@bib57]) into a *Braf ^f/f^; Raf1^f/f^* background ([@bib34]) ([Figure 1A](#fig1){ref-type="fig"}). The mice (heretofore referred to as Δ/Δep2) were born at Mendelian ratio but with their eyes open ([Figure 1B](#fig1){ref-type="fig"}), probably as a result of the migration defects of RAF1-deficient keratinocytes ([@bib20]). With time, however, they started to show symptoms of a progressive skin disease. These included intense itching and scratching resulting in partial alopecia and self-inflicted wounds ([Figure 1B](#fig1){ref-type="fig"}). Histological examination of the non-affected areas revealed thickening of the epidermis correlated with increased proliferation and expansion of both the basal and suprabasal keratinocytes but not with keratinocyte apoptosis ([Figure 1C](#fig1){ref-type="fig"} and [Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"}). Filaggrin (FLG) expression was similar to that of the controls ([Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"}). We also observed a rich dermal infiltrate comprised of activated (β1 Tryptase+) mast cells, granulocytes, dendritic cells and, less abundant, T cells and macrophages ([Figure 1C--D](#fig1){ref-type="fig"} and [Figure 1---figure supplement 1B](#fig1){ref-type="fig"}). In line with the dermal inflammatory reaction, Δ/Δep2 epidermis was characterized by the robust expression of the keratinocyte activation marker K6, of the cell adhesion molecule ICAM1, and by the sporadic expression of MHC class II molecules ([Figure 1E](#fig1){ref-type="fig"}), all upregulated in inflammatory conditions including atopic dermatitis ([@bib25]; [@bib22]; [@bib8]). Consistent with this, Δ/Δep2 epidermal lysates enriched in K5/K10-positive keratinocytes ([@bib17]) contained increased amounts of the cytokine TSLP, associated with skin allergic disorders ([@bib65]) ([Figure 1F](#fig1){ref-type="fig"}), as well as of other chemokines and cytokines, with CCL7, IL18, IL5 and IL13 levels significantly higher than controls ([Figure 1G](#fig1){ref-type="fig"}).10.7554/eLife.14012.003Figure 1.Compound deletion of BRAF and RAF1 in the epidermis leads to severe skin inflammation in adult mice.(**A**) BRAF and RAF1 are efficiently deleted in epidermal cells as shown by PCR analysis of tail tissue and immunoblotting of epidermal lysates isolated from 3 weeks old F/F2 and Δ/Δep2 (n = 4). ACTB is shown as a loading control. (**B**) Macroscopic appearance of newborn and adult F/F2 and Δ/Δep2 mice. Arrowhead highlights the open eye phenotype of Δ/Δep2 pups. (**C**) Hematoxylin/eosin (H and E) staining shows epidermal thickening and dermal inflammatory infiltrates in Δ/Δep2 mice. BrdU incorporation confirms hyperproliferation in the basal layer of Δ/Δep2 epidermis. The numbers in the inset represent BrdU^+^ cells/mm^2^ of epidermis (n = 5--7, mean ± SEM). Infiltrating cells: activated mast cells (β1 Tryptase^+^), granulocytes (esterase^+^), dendritic cells (CD11c^+^). (**D**) Quantification of the infiltrating cells: T cells (CD4^+^ and CD8^+^), macrophages (F4/80^+^), total mast cells (MC, toluidine blue^+^), granulocytes (GR, esterase^+^). (**E**) Increased expression of K6, ICAM1, and MHC II in Δ/Δep2 keratinocytes/epidermis. Representative images (**C, E**) and quantification (**D**) of 5--7 individual couples. Scale bars, 50 µm. (**F**) Inflammatory chemokines and cytokines in epidermal lysates (n = 3--4). TSLP levels were determined by immunoblotting and quantified by Image J. ACTB served as a loading control. The results were normalized by arbitrarily setting one of the F/F2 samples as 1 and plotted as mean ± SEM. Data represent mean ± SEM. p = 0.011, p1 = 0.001, p2 = 0.007, p3 = 0.001, p4 = 3.06E-6, p5 = 1.37E-4, p6 = 0.002, p7 = 0.049, p8 = 0.042, p9 = 0.046 and p10 = 0.001.**DOI:** [http://dx.doi.org/10.7554/eLife.14012.003](10.7554/eLife.14012.003)10.7554/eLife.14012.004Figure 1---figure supplement 1.Local inflammation in adult mice lacking BRAF and RAF1 in the epidermis.(**A**) Immunohistochemical analysis of epidermal differentiation (K5, K10 and FLG (filaggrin)) and apoptosis (TUNEL+). (**B**) Skin sections of adult F/F2 and △/△ep2 mice showing dermal infiltration: total mast cells (toluidine blue, TB^+^), macrophages (F4/80^+^) and T cells (CD4^+^ and CD8^+^). Arrows indicate positive cells. Quantification is shown in [Figure 1D](#fig1){ref-type="fig"} (n = 5--7). Scale bars, 50 µm.**DOI:** [http://dx.doi.org/10.7554/eLife.14012.004](10.7554/eLife.14012.004)

Epidermal ablation of BRAF and RAF1 had profound systemic effects. The mice failed to thrive ([Figure 2A](#fig2){ref-type="fig"}) and presented with enlarged spleens and lymph nodes. The splenomegaly could largely be attributed to increased numbers of Mac1+Gr1+ cells ([Figure 2B](#fig2){ref-type="fig"}), a cell type found both in the spleen of a mouse model of FITC contact hypersensitivity/*S. aureus* infection and in the blood and skin infiltrates of atopic dermatitis patients ([@bib54]). The lymph nodes contained elevated numbers of activated T, B, and dendritic cells ([Figure 2C](#fig2){ref-type="fig"}). In the blood, we observed leukocytosis and increased amounts of the chemokines CCL2 and CCL7, as well as of GCSF; in addition, serum IgEs were elevated in Δ/Δep2 mice ([Figure 2D](#fig2){ref-type="fig"}). Thus, the phenotype of adult Δ/Δep2 mice resembled a skin-specific allergic disease.10.7554/eLife.14012.005Figure 2.Inflammatory response in adult Δ/Δep2 animals.(**A**) The body weight of Δ/Δep2 mice is significantly reduced compared to their littermates (n = 5). The data was analyzed by two-way analysis of variance (ANOVA) test. (**B**) Increased spleen/body weight ratio and increased numbers of splenic Mac1^+^Gr1^+^ cells in adult Δ/Δep2 animals (n = 4--5). (**C**) Enlarged lymph nodes and and activated T, B, and dendritic cells in adult Δ/Δep2 (n = 4--8). T cells (CD4^+^ or CD8^+^) and B cells (B220^+^) activation was determined by costaining with CD69; activated dendritic cells were identified as CD11c^+^ and MHC II^hi^ or CD80^+^. (**D**) Circulating blood cells and plasma levels of chemokines and IgE antibodies in adult mice (n = 6--8). Data represent mean ± SEM. p1 = 0.0002, p2 = 0.023, p3 = 0.002, p4 = 0.002, p5 = 9.83E-8, p6 = 6.31E-7, p7 = 2.91E-7, p8 = 0.004, p9 = 0.001, p10 = 0.008, p11 = 0.011, p12 = 0.046, p13 = 0.050, p14 = 3.65E-4 and p15 = 0.001.**DOI:** [http://dx.doi.org/10.7554/eLife.14012.005](10.7554/eLife.14012.005)

To determine whether the systemic phenotype was secondary to the severe skin inflammation observed in adult animals, we examined Δ/Δep2 mice at weaning (3 weeks of age), at which stage they did not groom more than control littermates nor showed any signs of skin rash, except a mild eyelid irritation ([Figure 3---figure supplement 1A](#fig3s1){ref-type="fig"}). Skin architecture and keratinocyte proliferation were not altered at this stage ([Figure 3---figure supplement 1A](#fig3s1){ref-type="fig"}). In terms of dermal infiltrate, a 2-fold increase in mast cells could already be observed, but these cells were not activated ([Figure 3A](#fig3){ref-type="fig"} and [Figure 3---figure supplement 1A](#fig3s1){ref-type="fig"}). Granulocytes and dendritic cell numbers were indistinguishable in 3 weeks old F/F2 and Δ/Δep2 littermates ([Figure 3---figure supplement 1A](#fig3s1){ref-type="fig"}). In the epidermis, ICAM1 expression was slightly upregulated, while K6 and MHC II expression could not be detected ([Figure 3A](#fig3){ref-type="fig"} and [Figure 3---figure supplement 1B](#fig3s1){ref-type="fig"}). TSLP, CCL2, CCL7, and a number of cytokines (GMCSF, IL6, 4, 5, 13, 2) were already significantly elevated in the epidermal lysates, while only a trend could be observed for others ([Figure 3B](#fig3){ref-type="fig"} and [Figure 3---figure supplement 1C](#fig3s1){ref-type="fig"}). Systemically, enlarged lymph nodes contained increased amounts of activated T, B, and dendritic cells, while the spleen was normal both in size and cell composition ([Figure 3C](#fig3){ref-type="fig"} and [Figure 3---figure supplement 1D](#fig3s1){ref-type="fig"}). In the blood, the number of monocytes and granulocytes was increased, as were the levels of CCL2, CCL7, and GCSF. However, no significant difference in serum IgEs could be observed at this point ([Figure 3D](#fig3){ref-type="fig"}). The increase in T, B, and dendritic cells in lymph nodes and the granulocytosis could be traced as far back as 10 days of age, at which time point GCSF was the only cytokine elevated in the serum of Δ/Δep2 mice ([Figure 3E--F](#fig3){ref-type="fig"}). Thus, ablation of both *Braf* and *Raf1* in mouse epidermis does not directly disturb skin architecture but rather affects the cross-talk between keratinocytes and the innate and adaptive immune system.10.7554/eLife.14012.006Figure 3.Local and systemic inflammatory phenotype in young Δ/Δep2 animals.(**A**) Local inflammation in 3 weeks old Δ/Δep2 animals. Total mast cells (toluidine blue staining, TB; quantified in the plot, n = 4--5) and ICAM1 staining. Scale bars, 25 µm. (**B**) Inflammatory chemokines and cytokines in epidermal lysates (n = 4--5). TSLP levels were determined by immunoblotting and quantified and analyzed as in [Figure 1F](#fig1){ref-type="fig"}. TUBA served as a loading control. (**C, D**) Systemic inflammatory parameters in 3 weeks old mice. (**C**) Lymph node size and composition (n = 4). (**D**) Circulating blood cells (n = 8) and plasma concentration of IgE (n = 8) and chemokines (n = 9). (**E, F**) Systemic inflammatory parameters in 10 days old mice. (**E**) Lymph node size and composition (n = 4--10). (**F**) Hemogram showing elevated amounts of granulocytes (upper panel, n = 4--7) and plasma chemokine levels showing increased GCSF (n = 4). Data represent mean ± SEM. p1 = 0.016, p2 = 0.041, p3 = 0.013, p4 = 0.040, p5 = 0.013, p6 = 0.032, p7 = 0.026, p8 = 0.007, p9 = 0.029, p10 = 0.048, p11 = 0.015, p12 = 0.018, p13 = 0.033, p14 = 0.036, p15 = 3.00E-04, p16 = 3.88E-05, p17 = 0.026, p18 = 0.021, p19 = 0.048, p20 = 0.034, p21 = 0.042, p22 = 0.008, p23 = 0.001, p24 = 0.018, p25 = 0.005, p26 = 0.001, p27 = 0.001, p28 = 0.011 and p29 = 0.014.**DOI:** [http://dx.doi.org/10.7554/eLife.14012.006](10.7554/eLife.14012.006)10.7554/eLife.14012.007Figure 3---figure supplement 1.Local and systemic response in 3 weeks old △/△ep2 animals.(**A**) Eyelid inflammation in 3 weeks old △/△ep2 animals. Skin architecture (H&E), proliferation rate (percentage of BrdU^+^ cells in the epidermis), mast cells activation (β1 Tryptase^+^), granulocytes (esterase^+^) and dendritic cell (CD11c^+^) numbers are indistinguishable in 3 weeks old F/F2 and △/△ep2 littermates. Quantifications of the proliferating cells and granulocytes are shown in the insets (n = 3). (**B**) Three weeks old △/△ep2 epidermis does not express the activation markers K6 and MHC II. Scale bars, 25 µm. (**C**) Inflammatory chemokines and cytokines in 3 weeks old epidermal lysates (n = 5). (**D**) Normal spleen size and composition in 3 weeks old △/△ep2 mice (n = 4--6). Data represent mean ± SEM.**DOI:** [http://dx.doi.org/10.7554/eLife.14012.007](10.7554/eLife.14012.007)

Lack of epidermal BRAF and RAF1 causes transient inside-out barrier defects {#s2-2}
---------------------------------------------------------------------------

Inflammatory skin conditions often involve impaired skin barrier function. Δ/Δep2 embryos performed normally in an outside-in dye penetration assay, indicating that stratum corneum permeability was not affected ([Figure 4A](#fig4){ref-type="fig"}). We next monitored the weight of E18.5 embryos of different genotypes for 9 hr after birth as a proxy for transepidermal water loss and thus for the barrier function of tight junctions. Δ/Δep2 embryos lost three-fold the weight of littermate controls ([Figure 4B](#fig4){ref-type="fig"}). Molecularly, reduced expression of E-cadherin (CDH1), an adherens junction protein known to regulate tight junctions ([@bib60]), and of the tight junction protein claudin 1 (CLDN1), which is crucial for the maintenance of the inside-outside barrier ([@bib26]) and has been found downregulated in atopic dermatitis patients ([@bib13]) was still evident at P3 in Δ/Δep2 epidermis, while occludin expression was normal (OCLN) ([Figure 4C](#fig4){ref-type="fig"}). The architecture of P3 Δ/Δep2 skin was indistinguishable from that of controls ([Figure 4---figure supplement 1A](#fig4s1){ref-type="fig"}); P3 epidermal lysates contained highly variable amounts of chemokines and cytokines, predominantly CCL2, IL6 and IL18. All were increased in the Δ/Δep2 epidermal lysates, albeit not significantly ([Figure 4---figure supplement 1B](#fig4s1){ref-type="fig"}). The E-cadherin and claudin 1 downregulation was transient and was no longer detectable in 3 weeks old Δ/Δep2 mice ([Figure 4D](#fig4){ref-type="fig"}). Single deletion of RAF1 (RAF1Δ/Δep) and BRAF (BRAFΔ/Δep) did not lead to increased body weight loss in E18.5 embryos; consistently, the expression levels of tight junction proteins were normal in P3 epidermis ([Figure 4---figure supplement 1C--D](#fig4s1){ref-type="fig"}).10.7554/eLife.14012.008Figure 4.Transient inside-outside barrier defects in Δ/Δep2 animals.(**A**) Intact outside-in barrier function (determined by toluidine blue penetration of the stratum corneum) in E19.5-day-old Δ/Δep2 embryos compared to controls (n = 6). Representative pictures; two independent experiments were performed with identical results. (**B**) Increased water loss in the Δ/Δep2 E18.5 embryos as demonstrated by weight analysis. Results are displayed as percentage of initial weight (n = 41 for F/F2 and n = 11 for Δ/Δep2). The data was analyzed by two-way analysis of variance (ANOVA) test. (**C, D**) Immunoblot analysis of CDH1, CLDN1 and OCLN expression in epidermal lysates of 3 days old (**C**, n = 3; quantification shown in the plot, performed as in [Figure 1F](#fig1){ref-type="fig"}) or 3 weeks old Δ/Δep2 animals. TUBA and GAPDH are shown as loading controls. Data represent mean ± SEM. p1 = 0.0001, p2 = 0.028, p3 = 0.020.**DOI:** [http://dx.doi.org/10.7554/eLife.14012.008](10.7554/eLife.14012.008)10.7554/eLife.14012.009Figure 4---figure supplement 1.Skin architecture and inflammatory factors in 3 days old F/F2 and △/△ep2 animals.(**A**) Similar skin architecture in F/F2 and △/△ep2 pups based on H and E staining and on the analysis of differentiation markers (K5, K10 and involucrin). Scale bars, 50 µm. (**B**) Inflammatory chemokines and cytokines in epidermal lysates (n = 3). (**C**) Transepidermal water loss as determined by body weight analysis in E18.5 embryos lacking either BRAF (BRAFΔ/Δep) or RAF1 (RAF1Δ/Δep) in the epidermis (n = 10 for F/F2, n = 4 for Δ/Δep2, n = 3 for BRAFΔ/Δep and n = 6 for RAF1Δ/Δep). The data was analyzed by two-way analysis of variance (ANOVA) test. (**D**) Expression levels of tight junction proteins in the epidermis of P3 BRAFΔ/Δep or RAF1Δ/Δep pups quantified and plotted as in [Figure 1F](#fig1){ref-type="fig"} (n = 3). TUBA is used as a loading control. Data represent mean ± SEM. p1 = 0.0442.**DOI:** [http://dx.doi.org/10.7554/eLife.14012.009](10.7554/eLife.14012.009)

To assess the relevance of the transient perinatal barrier defect of Δ/Δep2 mice, we deleted *Braf* and *Raf1* in 3 weeks old mice using tamoxifen-inducible Krt5-Cre ([@bib30]). These animals, termed Δ/Δep2^TX^, showed conversion of both F to Δ alleles and strongly reduced expression of BRAF and RAF1 proteins in tail tissue ([Figure 5A](#fig5){ref-type="fig"}). Δ/Δep2^TX^ mice developed a milder disease than the Δ/Δep2 mice, characterized by much slower kinetics (8 months between ablation and overt symptoms), moderate keratinocyte hyperproliferation (assessed as increased epidermal thickness) and activation (as determined by K6 and ICAM1 expression), as well as by a modest increase in activated mast cells and granulocytes in the dermis ([Figure 5B](#fig5){ref-type="fig"}). At the systemic level, we observed mild splenomegaly with an increase in Mac1+Gr1+ cells ([Figure 5C](#fig5){ref-type="fig"}) as well as enlarged lymph nodes containing activated lymphocytes and dendritic cells ([Figure 5D](#fig5){ref-type="fig"} and [Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}). Increased numbers of lymphocytes and granulocytes were found in the blood, while IgE levels were comparable to controls ([Figure 5E](#fig5){ref-type="fig"}). Thus, circumventing the transient barrier defect of the Δ/Δep2 animals postponed and attenuated the clinical manifestation of the disease.10.7554/eLife.14012.010Figure 5.Local and systemic inflammation in Δ/Δep2^TX^ mice.(**A**) PCR analysis of tail tissue (left) and immunoblot analysis of epidermal lysates obtained from Δ/Δep2^TX^ animals. (**B**) Macroscopic appearance of Δ/Δep2^TX^ mice and histological analysis of H&E sections. Scale bars, 25 µm. Infiltrating cells: mast cells (MC; TB^+^), activated mast cells (β1 Tryptase^+^; modest), granulocytes (GR; esterase^+^). The plot shows a quantification of the histological analysis. (**C**) Mild splenomegaly with increased numbers of Mac1^+^Gr1^+^ cells in Δ/Δep2^TX^ animals. (**D**) Activated T cells, B cells and dendritic cells in the lymph nodes of Δ/Δep2^TX^ animals. (**E**) Mild lymphocytosis and significantly elevated granulocyte numbers in Δ/Δep2^TX^ mice. The right panel shows comparable IgE plasma levels in control and Δ/Δep2^TX^ animals. Data are plotted as mean ± SEM (n = 5; p1 = 0.034, p2 = 0.014, p3 = 0.005, p4 = 2.63E-4, p5 = 0.001, p6 = 0.001, p7 = 0.019 and p8 = 0.042).**DOI:** [http://dx.doi.org/10.7554/eLife.14012.010](10.7554/eLife.14012.010)10.7554/eLife.14012.011Figure 5---figure supplement 1.Representative FACS analysis of lymph node and spleen cells isolated from adult F/F2^TX^ Δ/Δep2^TX^ animals.The percentage of activated lymphocytes in lymph nodes was assessed by combining lineage specific markers (CD4 and CD8 for T lymphocytes; B220 for B lymphocytes) with the activation marker CD69. Activated dendriditic cells were identified by staining with CD11c and MHC II antibodies. Myeloid cells in the spleen were analyzed by staining with Mac1 and Gr1 antibodies. The percentage of single and double positive cells is indicated.**DOI:** [http://dx.doi.org/10.7554/eLife.14012.011](10.7554/eLife.14012.011)

Increased JNK and reduced ERK activation in Δ/Δep2 epidermis and cells {#s2-3}
----------------------------------------------------------------------

To gain insight in the molecular correlates of the phenotype, we analyzed MAPK signaling in the epidermis. We observed decreased activation of ERK and increased activation of JNK, assessed by the phosphorylation of both MAPK and their respective downstream targets pRSK and pJUN, in non-lesional epidermis of adult Δ/Δep2 and Δ/Δep2^TX^ mice; in contrast, phosphorylation of the p38 target MAPKAPK2 was not affected ([Figure 6A and B](#fig6){ref-type="fig"}). A more detailed analysis of 3 weeks old animals confirmed low ERK activation and increased phosphorylation of JNK (and, to a lower degree, p38) in Δ/Δep2 epidermal lysates ([Figure 6C](#fig6){ref-type="fig"}). Consistent with this phosphorylation pattern, the levels of the dual specificity phosphatase DUSP1 and DUSP10, negative regulators of the stress kinases ([@bib48]), were low in the Δ/Δep2 lysates. BRAFΔep lysates were characterized by reduced ERK phosphorylation only, while RAF1Δep lysates showed increased phosphorylation of all three MAPK. The expression of ICAM1 as marker of inflammation was detected only in the Δ/Δep2 lysates, leading to the hypothesis that the combination of high JNK, low ERK activation is at the basis of the inflammatory phenotype of Δ/Δep2 animals ([Figure 6C](#fig6){ref-type="fig"}).10.7554/eLife.14012.012Figure 6.Molecular consequences of BRAF/RAF1 deletion in primary keratinocytes and epidermis.(**A, B**) Immunohistochemical analysis of pERK and pJNK, their downstream targets pRSK and pJUN, and the p38 downstream target pMAPKAPK2 in adult F/F2 and Δ/Δep2 (**A**), and F/F2^TX^ Δ/Δep2^TX^ epidermis (**B**). Scale bars, 50 µm. The plots on the right show the percentage of positive cells in the epidermis (n = 4--5). (**C**) Immunoblot analysis of MAPK signaling in 3 weeks old epidermal lysates (n = 4), quantified as in [Figure 1F](#fig1){ref-type="fig"}. ACTB is shown as a loading control. Phosphorylation is expressed as the ratio between the signals obtained obtained with the phosphospecific antibody and with the protein-specific antibody. In both cases, the data are normalized to one of the F/F2 samples, which was arbitrarily set as 1. Data are plotted as mean ± SEM. p1 = 2.73E-4, p2 = 4.15E-5, p3 = 0.042, p4 = 0.031, p5 = 0.001, p6 = 0.023, p7 = 0.038, p8 = 0.049, p9 = 0.010, p10 = 0.030, p11 = 0.033, p12 = 0.023 and p13 = 0.018.**DOI:** [http://dx.doi.org/10.7554/eLife.14012.012](10.7554/eLife.14012.012)

Inhibition of ERK activation induces inflammatory skin disease in RAF1Δep mice {#s2-4}
------------------------------------------------------------------------------

We tested this hypothesis by treating 6 weeks old RAF1Δep animals with a MEK inhibitor (MEKi; trametinib, in clinical use; daily by gavage for 32 days) to decrease ERK activation and determine whether this would phenocopy the Δ/Δep2 disease. MEKi efficiently reduced ERK phosphorylation and slightly increased JNK phosphorylation in both control and RAF1Δep epidermal lysates, but increased p38 phosphorylation was only observed in the RAF1Δep ([Figure 7A](#fig7){ref-type="fig"}). Consistently, MEKi reduced the expression of the phosphatases DUSP1 and 10 and of CLDN1 in RAF1Δep epidermis only ([Figure 7A](#fig7){ref-type="fig"}). Within a month, the RAF1Δep animals developed an inflammatory skin disease characterized by K6 and ICAM1 expression in the epidermis, by the presence of activated dermal mast cells and by an increase in TSLP ([Figure 7B](#fig7){ref-type="fig"}). In control animals, inhibitor treatment did not affect, or reduced chemo- or cytokine amounts; GMCSF, IL5, IL2 and CCL4 were reduced significantly, and a trend could be observed for IL4, IL17, IL27, and CXCL1. In contrast, a comparison between inhibitor-treated RAF1F/F and RAF1Δep lysates revealed a significant upregulation of CCL2, GMCSF, IL18, IL5, IL13, IL2, IL17 and CCL4 ([Figure 7C](#fig7){ref-type="fig"} and [Figure 7---figure supplement 1](#fig7s1){ref-type="fig"}). This correlated with increased Mac1+Gr1+ cells in the spleen and activated T, B, and dendritic cells in the lymph nodes ([Figure 7D](#fig7){ref-type="fig"}) as well as with increased circulating IgEs and granulocytosis ([Figure 7E](#fig7){ref-type="fig"}). Thus, inhibiting ERK in the RAF1Δep animals recreates the immunological environment necessary to bring about a disease very similar to that observed in Δ/Δep2 mice.10.7554/eLife.14012.013Figure 7.MEK/ERK inhibition in RAF1Δep animals phenocopies the Δ/Δep2 phenotype.RAF1Δep animals were treated with a MEK inhibitor (MEKi; trametinib, daily by gavage for 32 days). (**A**) Immunoblot of epidermal lysates showing the effect of MEKi on the phosphorylation and expression of the indicated proteins. GAPDH is shown as a loading control. (**B**) Macroscopic appearance (top panels) and histological analysis of vehicle versus MEKi-treated animals. Mast cells (TB^+^) and activated mast cells (β1 Tryptase^+^) are quantified in the plots on the left. Scale bars 25 μm. (**C**) Inflammatory chemokines and cytokines in epidermal lysates of MEKi treated-mice. TSLP levels were determined by immunoblotting and quantified and analyzed as in [Figure 1F](#fig1){ref-type="fig"}. ACTB served as a loading control. (**D**) Increased numbers of splenic Mac1^+^ Gr1^+^ cells and of activated T cells, B cells and dendritic cells in the lymph nodes of MEKi-treated RAF1Δep animals. (**E**) Mild monocytosis and granulocytosis in MEKi-treated RAF1Δep animals and elevated amount of plasma IgE. Data represent mean ± SEM (n = 3; p1 = 0.002, p2 = 0.017, p3 = 0.003, p4 = 0.025, p5 = 0.041, p6 = 0.022, p7 = 0.023, p8 = 0.029, p9 = 0.010, p10 = 0.032, p11 = 0.044, p12 = 0.053, p13 = 0.015, p14 = 0.001, p15 = 0.031, p16 = 0.049, p17 = 0.026, p18 = 0.038, p19 = 0.015, p20 = 0.001, p21 = 0.005, p22 = 0.002, p23 = 0.033, p24 = 0.006, p25 = 0.039, p26 = 0.025, p27 = 0.004, p28 = 0.020, p29 = 0.027 and p30 = 0.028).**DOI:** [http://dx.doi.org/10.7554/eLife.14012.013](10.7554/eLife.14012.013)10.7554/eLife.14012.014Figure 7---figure supplement 1.Epidermal chemokine and cytokine levels in MEKi treated mice.Inflammatory chemokines and cytokines in epidermal lysates of vehicle or MEKi treated mice. Data represents mean ± SEM (n = 3; p1 = 0.043, p2 = 0.054 and p3 = 0.029).**DOI:** [http://dx.doi.org/10.7554/eLife.14012.014](10.7554/eLife.14012.014)

The inflammatory skin disease of Δ/Δep2 mice can be prevented by JNK inhibition but not by MyD88, TNF or caspase 1/11 ablation {#s2-5}
------------------------------------------------------------------------------------------------------------------------------

Collectively, the data above suggest that JNK activation was responsible for the inflammatory skin phenotype. To assess whether this was the case in vivo, we treated Δ/Δep2 animals with the specific peptide inhibitor D-JNKI1. D-JNKI1 efficiently blocked JUN phosphorylation, increased ERK and RSK phosphorylation ([Figure 8A](#fig8){ref-type="fig"}), and prevented the development of the disease as determined by ICAM1 and TSLP expression in the epidermis as well as by eyelid inflammation and mast cells accumulation in the dermis ([Figure 8A--B](#fig8){ref-type="fig"}). Consistent with the data in [Figure 3---figure supplement 1B](#fig3s1){ref-type="fig"}, K6 expression could not be observed in the interfollicular epidermis in any of the experimental groups ([Figure 8---figure supplement 1A](#fig8s1){ref-type="fig"}). Compared to untreated 3 weeks old animals, vehicle (TAT-peptide) alone had minor effects on the level of some chemokines and cytokines; the increase in IL17 and IL18 in TAT-peptide-treated Δ/Δep2 vs F/F2 animals became significant; the opposite was observed for CCL7, IL13 and IL4 (compare [Figures 3B](#fig3){ref-type="fig"} and [8C](#fig8){ref-type="fig"}; and [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"} with [Figure 8---figure supplement 1B](#fig8s1){ref-type="fig"} ). Treatment with D-JNKI1 reduced chemo- and cytokines in epidermal lysates of Δ/Δep2 animals to levels indistinguishable from, or lower than (CCL2, CCL4, GMCSF and IL4), those of F/F2 controls. Exceptions were IL6, which was significantly reduced in Δ/Δep2, but not in F/F2 epidermal lysates; and IL5, which was not affected by the inhibitor in either genotype ([Figure 8C](#fig8){ref-type="fig"} and [Figure 8---figure supplement 1B](#fig8s1){ref-type="fig"}). At the systemic level, D-JNKI1 normalized the numbers of activated B and dendritic cells in lymph nodes, while the numbers of activated T cells where reduced in both F/F2 and Δ/Δep2 lymph nodes ([Figure 8D](#fig8){ref-type="fig"}). Thus, JNK activation and the resulting chemo- and cytokine accumulation in the epidermis are required for disease development.10.7554/eLife.14012.015Figure 8.D-JNKI1 treatment rescues inflammation in Δ/Δep2 mice.Mice were treated with D-JNKI1 or TAT peptide (22 mg/kg i.p. at 10 days of age) and analyzed after 12 days (**A**) D-JNKI1 treatment prevents disease onset in Δ/Δep2 mice. Immunoblot of epidermal lysates showing the effect of D-JNKI1 on the phosphorylation and expression of the indicated proteins, quantified as in [Figure 1F](#fig1){ref-type="fig"}. ACTB is shown as a loading control. (**B--D**) Decreased eyelid inflammation, mast cells infiltration (**B**; TB^+^; quantified in the plot on the right), epidermal chemokine/cytokine levels (**C**) and activated T cells, B cells and dendritic cells in lymph nodes (**D**) in D-JNKI1-treated Δ/Δep2 mice. Scale bars, 25 µm. Data represent mean ± SEM (n = 3--5; p1 = 0.026, p2 = 0.042, p3 = 0.022, p4 = 0.048, p5 = 0.044, p6 = 0.020, p7 = 0.025, p8 = 0.018, p9 = 0.016, p10 = 0.014, p11 = 0.023, p12 = 0.011, p13 = 0.039, p14 = 0.049, p15 = 0.015, p16 = 0.003, p17 = 1.70E-4, p18 = 0.008, p19 = 0.008, p20 = 0.004, p21 = 0.003, p22 = 0.017, p23 = 0.026, p24 = 0.027, p25 = 0.005, p26 = 2.13E-6, p27 = 4.50E-8, p28 = 1.39E-5, p29 = 0.001, p30 = 0.001, p31 = 0.001, p32 = 0.023, p33 = 2.35E-4, p34 = 0.050, p35 = 0.002, p36 = 0.050 and p37 = 0.012).**DOI:** [http://dx.doi.org/10.7554/eLife.14012.015](10.7554/eLife.14012.015)10.7554/eLife.14012.016Figure 8---figure supplement 1.K6 expression and epidermal chemokine and cytokine levels in D-JNKI1-treated mice.(**A**) K6 expression is indistinguishable in TAT or D-JNKI1 treated F/F2 and △/△ep2 littermates. Scale bars, 25 µm. (**B**) Inflammatory chemokines and cytokines in epidermal lysates of TAT or D-JNKI1-treated mice. Data represent mean ± SEM (n = 3--5; p1 = 0.005, p2 = 0.001, p3 = 0.043, p4 = 0.026, p5 = 0.032, p6 = 0.016 and p7 = 0.051).**DOI:** [http://dx.doi.org/10.7554/eLife.14012.016](10.7554/eLife.14012.016)10.7554/eLife.14012.017Figure 8---figure supplement 2.The inflammatory phenotype of Δ/Δep2 mice is not rescued by MyD88, caspase 1/11, or TNF knockout.Macroscopic appearance, spleen and lymph node size and circulating blood cell analysis are shown for the indicated genotypes (**A--C**). (**A**) Representative pictures of 4 month old Δ/Δep2, Δ/Δep2 MyD88^-/-^ and control animals. Plots on the right represent the ratio between total splenocytes or lymph node cell numbers and body weight (n = 3--4). (**B**) Representative pictures and hemogram of 4 month old Δ/Δep2, Δ/Δep2 caspase 1/11^-/-^ and control animals (n = 5--6). (**C**) Representative pictures and hemogram of 4 month old Δ/Δep2, Δ/Δep2 TNF^-/-^ and control animals (n = 4--5). The macroscopic appearance of at least ten mice per genotype was monitored. Data represent mean ± SEM. p1 = 0.041, p2 = 0.052, p3 = 0.024, p4 = 0.023, p5 = 0.026, p6 = 0.034, p7 = 0.023, p8 = 0.007, p9 = 0.031, p10 = 0.011, and p11 = 0.034.**DOI:** [http://dx.doi.org/10.7554/eLife.14012.017](10.7554/eLife.14012.017)

To determine whether the increased JNK activation observed in the Δ/Δep2 animals was due to a specific signal, we mated them to MyD88 knockout animals ([@bib1]), to block both TLR (with the exception of TLR3) and IL1 signaling ([@bib31]). We also used TNFA knockout mice to prevent TNF signaling ([@bib37]), and caspase 1/11 knockout mice to ablate IL1 and IL18 production ([@bib55]). None of these knockouts altered the progression (onset around 2 months of age) or severity of the Δ/Δep2 skin disease ([Figure 8---figure supplement 2](#fig8s2){ref-type="fig"}). The Myd88 knockout, however, reduced the splenomegaly observed in the Δ/Δep2 mice. This specific phenotype is caused by an increase in Mac1+/Gr1+ splenocytes ([Figure 2B](#fig2){ref-type="fig"}), and its selective rescue in the compound Δ/Δep2;MyD88 knockout animals is likely due to the crucial role of MyD88 in the generation of these cells ([@bib3]; [@bib15]).

Interfering with the JNK pathway decreases the production of proinflammatory molecules in primary Δ/Δep2 keratinocytes and RAF knockdown HaCat cells {#s2-6}
----------------------------------------------------------------------------------------------------------------------------------------------------

A concomitant increase in JNK activation and decrease in ERK activation is the basis of the skin disease of Δ/Δep2 animals. To test whether this molecular phenotype was cell-autonomous and to gain some insight in the molecular mechanisms underlying JNK activation, we established and analyzed primary keratinocytes cultures. Δ/Δep2 keratinocytes were "primed" for inflammation: they constitutively expressed ICAM1 ([Figure 9A](#fig9){ref-type="fig"}) and, upon stimulation, significantly increased amounts of chemokines (CCL2, CCL7) and cytokines (IL6, IL18, TSLP, IL13, [Figure 9B](#fig9){ref-type="fig"}; IL4 was not detected under these conditions). In addition, Δ/Δep2 keratinocytes showed decreased ERK activation in response to EGF and a strong increase in pJNK when co-treated with proinflammatory stimuli ([Figure 9A](#fig9){ref-type="fig"}). Treatment with D-JNKI1, a cell-penetrating, protease-resistant peptide that prevents JNK interaction with its JBD-dependent targets ([@bib7]), reduced the expression of the inflammatory proteins ICAM1, TSLP, CCL2 and CCL7, but did not have any major effect on ERK activation and on the stress kinase phosphatases DUSP1 and DUSP10, expressed at lower levels in Δ/Δep2 keratinocytes ([Figure 9C--D](#fig9){ref-type="fig"}).10.7554/eLife.14012.018Figure 9.Increased stress kinase signaling and JNK pathway-dependent cytokine and chemokine production by primary keratinocytes lacking BRAF and RAF1.(**A**) Reduced ERK phosphorylation and increased JNK/p38 activation in primary Δ/Δep2 keratinocytes stimulated with EGF and/or TNFα and IL1β for 15 min. (**B**) Increased cytokine and chemokine production in primary Δ/Δep2 keratinocytes treated with EGF, TNFα and IL1β for 24 hr. Cytokine and chemokine production was determined by multiplex analysis, except for TSLP which was quantified by ELISA. Data represent mean ± SEM of 3--5 biological replicates. (**C--D**) Cells were pretreated with D-JNKI1 inhibitors prior to stimulation with EGF, TNFα and IL1β for 15 min (**C**) or 24 hr (**D**). Data represent the mean ± SEM of technical replicates (n = 3). (**E--F**) Effect of shRNA-mediated *Mlk3* silencing on ERK and JNK phosphorylation and ICAM1 expression (**E**; stimulation with EGF, TNFα and IL1β for 15 min) and on the expression of *Ccl2* and *Tslp* mRNA (**F**; stimulation with EGF, TNFα and IL1β for 24 hr) by F/F2 and Δ/Δep2 keratinocytes. shRen, shRNA targeting Renilla, used as a control; sh1 and sh2, targeting *Mlk3*, binding sites nucleotide 2266--2285 and 2383--2402, respectively. The shRNAs were encoded by lentiviral vectors coexpressing GFP. GFP immunoblots are shown to confirm similar levels of infection in all samples. Data represent mean ± SEM of 4 biological replicates. Each keratinocyte culture represents a pool of three mice. Immunoblots are representative of three independent experiments. p1 = 0.041, p2 = 0.040, p3 = 1.89E-4, p4 = 0.018, p5 = 0.046, p6 = 0.020, p7 = 0.008, p8 = 0.016, p9 = 0.001, p10 = 0.018, p11 = 3.23E-4, p12 = 1.47E-4, p13 = 0.007, p14 = 0.03, p15 = 0.035, p16 = 0.023 and p17 = 0.046.**DOI:** [http://dx.doi.org/10.7554/eLife.14012.018](10.7554/eLife.14012.018)10.7554/eLife.14012.019Figure 9---figure supplement 1.Compound knockdown (KD2) of *BRAF* and *RAF1* induce the expression of inflammation markers by HaCat cells in a MLK3/JNK-dependent manner.(**A**) Reduced ERK and increased JNK/p38 activation in *BRAF* and *RAF1* knockdown (KD2) HaCat cells stimulated with EGF, TNFα and IL1β for 15 min. (**B**) D-JNKI1 reduces ICAM1 and *CCL2* (n = 4) expression in KD2 cells treated with TNFα. (**C**) MEKi induces ICAM1 and *CCL2* (n = 3) expression in RAF1KD cells treated with TNFα. In (**B--C**), ICAM1 expression was measured after a 3 hr, *CCL2* expression after a 24 hr treatment with TNFα. (**D**) Effect of *MLK3* silencing on ERK and JNK phosphorylation in WT and KD2 cells stimulated as in (**A**). MLK3 was silenced using a pool of oligonucleotides targeting the following regions: 686--704; 1489--1507; 2122--2138; and 2348--2366. MLK3 KD cells stimulated as in (**B--C**) show a decrease in JNK activation, ICAM1 and *CCL2* (n = 7) expression. Immunoblots are representative of three independent experiments. qPCR data represent mean ± SEM of three independent experiments run in duplicates (p1 = 4.62E-4, p2 = 0.013, p3 = 0.050, p4 = 8.60E-8, p5 = 0.050, p6 = 0.001, p7 = 0.001 and p8 = 0.012).**DOI:** [http://dx.doi.org/10.7554/eLife.14012.019](10.7554/eLife.14012.019)

To ensure that the effects observed in the Δ/Δep2 cells and tissue could be reproduced by acute ablation, we performed knockdown experiments in the human keratinocyte cell line HaCat. Concomitant silencing of *BRAF* and *RAF1* (double knockdown, KD2) abolished basal ERK phosphorylation, decreased ERK activation and increased JNK activation by a combination of EGF and proinflammatory stimuli ([Figure 9---figure supplement 1A](#fig9s1){ref-type="fig"}). Constitutive ICAM1 expression was not observed in KD2 cells, but they expressed higher levels of this molecule when treated with TNFα. ICAM1 expression was reduced by D-JNKI1 in KD2 cells and increased by MEKi in RAF1KD cells ([Figure 9---figure supplement 1B--C](#fig9s1){ref-type="fig"}). *CCL2* mRNA accumulation, which depends on concomitant stress kinase activation and ERK inhibition, was also elevated in a JNK-dependent manner in KD2 cells ([Figure 9---figure supplement 1B](#fig9s1){ref-type="fig"}); MEK inhibition strongly increased *CCL2* mRNA in WT cells ([@bib47]) and even more so in RAF1KD cells ([Figure 9---figure supplement 1C](#fig9s1){ref-type="fig"}).

Mixed lineage kinase 3 (MLK3) activates the JNK pathway ([@bib27]) and can function both as a positive regulator of ERK signaling, via kinase-independent mechanisms ([@bib10]; [@bib11]) and as a negative regulator of ERK, via JNK-dependent mechanisms ([@bib53]). Importantly, MLK3 binds to JIP1 ([@bib61]), and signal flow from this upstream kinase would be interrupted by D-JKNI1. We thus determined whether MLK3 was implicated in the imbalance in ERK/JNK signaling observed in Δ/Δep2 primary keratinocytes and in KD2 HaCat cells. MLK3 downregulation by two independent shRNAs strongly reduced both ERK and JNK phosphorylation in F/F2 cells treated with EGF and proinflammatory stimuli; however, in Δ/Δep2 cells, only JNK phosphorylation was reduced ([Figure 9E](#fig9){ref-type="fig"}). Consistently, MLK3 downregulation reduced ICAM1 upregulation and the induction of *Ccl2* and *Tslp* mRNA ([Figure 9F](#fig9){ref-type="fig"}). Essentially the same results were obtained by downregulating MLK3 in WT and KD2 HaCat cells ([Figure 9---figure supplement 1D](#fig9s1){ref-type="fig"}). Thus, MLK3 is responsible for JNK activation and the induction of inflammatory molecules in Δ/Δep2 keratinocytes and HaCat cells.

Discussion {#s3}
==========

BRAF and RAF1 prevent keratinocyte-driven allergic inflammation {#s3-1}
---------------------------------------------------------------

Keratinocytes have long been known to contribute to the pathogenesis of skin inflammatory disorders, but whether they do so by reacting to stimuli produced by immune cells or by initiating the cascade leading to the disease is still a matter of debate. We describe an essential role of BRAF and RAF1 in keratinocytes in the control of allergic inflammation. Mice lacking BRAF/RAF1 in keratinocytes develop a disease clinically very similar to human atopic dermatitis ([@bib5]). It starts with a barrier defect accompanied by the reduced expression of crucial tight junction proteins and by a marginally increased expression of chemokines and cytokines, particularly CCL2, IL6 and IL18. It then progresses to a stage in which the skin appears unaffected, yet both local (mast cell infiltration, chemokine and cytokine production) and systemic (T and B cell activation, increased amounts of circulating leukocytes and chemokines) anomalies become evident while TSLP and IgE levels are only slightly increased. This is reminiscent of the early phase of atopic dermatitis in children, prior to IgE sensitization ([@bib5]). Unlike the majority of atopic dermatitis patients ([@bib14]), however, the Δ/Δep2 animals don't have a stratum corneum defect, which may help explain the lack of symptoms at this stage. Adult mice present with a full-fledged disease characterized by rich dermal infiltrates, increased cytokine production, clearly elevated IgEs and mast cell activation, in good correlation with the intense pruritus causing extensive scratching and self-inflicted wounds. The initial barrier defect contributes to full-fledged disease, since ablation of BRAF/RAF1 after the third week causes a less severe condition lacking IgE sensitization and mast cell activation, yet recapitulating the systemic symptoms of the disease. This could be likened to late-onset, IgE-sensitization-independent dermatitis ([@bib5]). Thus, BRAF and RAF1 act together to ensure the timely establishment of the inside-out barrier of the epidermis and to prevent allergic inflammation. The data support the hypothesis that the keratinocytes play a primary role in the pathogenesis of atopic dermatitis, and the Δ/Δep2 animals may be useful as a model for this disease ([Figure 10](#fig10){ref-type="fig"}).10.7554/eLife.14012.020Figure 10.Molecular and physiological defects in mice lacking BRAF and RAF1 in the epidermis.Compound BRAF/RAF1 ablation in keratinocytes induces an imbalance in MAPK signaling, resulting in low ERK, high JNK activation. This causes early inside-outside barrier defects accompanied by reduced CDN1 expression (yellow arrows), followed by a breakdown of the immunological barrier and local as well as systemic allergic inflammation akin to atopic dermatitis, characterized by the presence of Th2 cytokines in the epidermis. The phenotype can be prevented by inhibiting the JNK pathway in Δ/Δep2 animals and cells, and phenocopied by inhibiting the ERK pathway in Raf1Δ/Δep animals. Systemic effects (lymph node involvement, circulating IgEs) are separated from local effect by a dashed line. B (B cells), T (T cells), Mc (Mast cells), D (dendritic cells).**DOI:** [http://dx.doi.org/10.7554/eLife.14012.020](10.7554/eLife.14012.020)

A set of chemokines and Th2 cytokines underlies Δ/Δep2 allergic inflammation {#s3-2}
----------------------------------------------------------------------------

In this respect, our experiments provide information about the minimal set of keratinocyte-derived factors required for the establishment of allergic, atopic dermatitis-like inflammation.

In the phase before IgE sensitization and mast cell activation, we detected significantly higher levels of TSLP, CCL2, CCL7, GMCSF, IL2, IL5, IL6, and IL13 in Δ/Δep2 epidermal lysates; most chemokines and cytokines in the Δ/Δep2 animals were sensitive to D-JNKI1 inhibitor treatment, which brought Δ/Δep2 and F/F2 epidermal lysates down to indistinguishable levels. Conversely, the set of cytokines (TSLP, IL5, IL13, IL18, borderline IL2 and IL17) observed in adult, diseased Δ/Δep2 mice was similar to that promoting symptomatic disease in RAF1Δep animals treated with trametinib, which showed an increase in TSLP, IL2, IL5, IL13, as well as in IL18. These data can be interpreted to mean that ERK signaling negatively regulates the production of allergy-promoting factors. However, it is important to note that trametinib treatment reduced IL2 and IL5 as well as GMCSF in the F/F2 epidermis, indicating that sensitivity to ERK inhibition must be seen in the context of altered cell-autonomous signaling (increased JNK activation in RAF1Δep epidermis) and/or tissue milieu. Along the same lines, Δ/Δep2 keratinocytes treated with inflammatory stimuli were significantly more efficient than F/F2 in producing CCL2, CCL7, IL6, IL18, TSLP and IL13, but not IL2 or IL5, resembling, but not fully reproducing, the spectrum observed in epidermal lysates. At this stage, it is impossible to determine whether these discrepancies might be due to the presence of cell types other than keratinocytes in the epidermal lysates or whether the culture and stimulation conditions used did not recapitulate the situation in vivo.

Be that as it may, the range of chemokines and cytokines overrepresented in the Δ/Δep2 mice and in the trametinib-treated RAF1Δep mice is consistent with allergic inflammation. In this respect, strong expression of CCL2 has been reported in the basal keratinocytes of atopic dermatitis patients ([@bib28]), and expression of CCL7, which can attract basophils, eosinophils, mast cells and Th2 cells, can be induced by allergens in atopic skin ([@bib63]).

TSLP, the signature cytokine of allergic disease, promotes the functions of these same cell types ([@bib65]), and is responsible for the extreme itching accompanying atopic dermatitis ([@bib62]). High levels of TSLP ([@bib41]), but also of IL5 and IL13 have been reported in the skin of atopic dermatitis patients, particularly in those with elevated IgEs ([@bib32]). In mice, it could be shown that the expression of TSLP ([@bib41]), IL4, IL5 and IL13 induces atopic dermatitis as well as asthma ([@bib39]), and IL5 knockout mice exposed to allergens are less prone than wild-type to develop skin eosinophilia and epidermal thickening ([@bib56]). Finally, expression of IL13 in keratinocytes is sufficient to induce a disease mimicking atopic dermatitis ([@bib64]). Thus, these cytokines appear instrumental for the development of atopic dermatitis with IgE sensitization. IL18, on the other hand, can stimulate both Th1 and Th2 responses ([@bib44]), and appears to be causally involved in a different type of atopic dermatitis. IL18 is essential for the induction of dermatitis by the epidermis-restricted expression of caspase 1, the enzyme that generates active IL18 from its precursor. In addition, expression of IL18 in keratinocytes induces a late-onset dermatitis associated with mastocytosis, but independent of IgE production ([@bib36]). More recently, IL18 knockout mice were shown to be resistant to infection-associated atopic dermatitis, in a mouse model generated by perturbing the stratum corneum with detergent prior to topical application of *S. aureus* protein A ([@bib59]). However, stratum corneum defects could not be observed in Δ/Δep2 mice, and caspase 1 ablation does not modify the course of the Δ/Δep2 disease. Thus, IL18 is not a determining factor in the context of the Δ/Δep2 dermatitis, which rather resembles a Th2/IgE-driven disease.

An imbalance in MAPK signaling underlies skin inflammation in Δ/Δep2 mice {#s3-3}
-------------------------------------------------------------------------

Ablation of BRAF and RAF1 in the epidermis has non-redundant functions converging on MAPK cascades. Decreased ERK and increased JNK activation are observed in Δ/Δep2 epidermis in vivo independently of the severity of the disease as well as in Δ/Δep2 keratinocytes and BRAF/RAF1 knockdown HaCat cells. Thus, the imbalance in MAPK signaling represents an intrinsic defect of cells and tissues lacking BRAF/RAF1. While BRAF ablation, as in many other tissues/organs, is responsible for reduced ERK activation ([@bib16]), RAF1 ablation correlates with a previously unnoticed increase in stress kinase activation. Consistent with this, we have observed a reduction in the expression of two DUSPs involved in the inactivation of stress kinases, which is strongest in the Δ/Δep2 epidermis. This is in line with the reported positive role of p38 in the induction of DUSP expression and of ERK in its attenuation at multiple levels ([@bib9]; [@bib58]), which would predict that decreased ERK signaling would be needed to reduce DUSP expression and stabilize JNK phosphorylation when p38 is active. Importantly, both DUSPs have been implicated in the production of cytokines by immunocompetent cells and in murine models of inflammatory and autoimmune disease ([@bib38]).

We could further identify MLK3 as the kinase responsible for JNK activation as well as for the expression of inflammatory molecules in primary Δ/Δep2 keratinocytes and BRAF/RAF1 knockdown HaCat cells costimulated with EGF, TNFα and IL1β (as a proxy for the alterations observed in the Δ/Δep2 animals). The lack of basal JNK activation in unstimulated cells suggests a cross-talk at the level of BRAF/RAF1 and MLK3 rather than direct MLK3 activation by BRAF/RAF1 ablation. Such a cross-talk was previously reported to occur in the context of ERK signaling, which is positively regulated by MLK3 via the stabilization of the RAF dimer ([@bib10]; [@bib11]). It is possible that in turn, BRAF and RAF1 would restrict the involvement of MLK3 in the JNK pathway, at the same time promoting ERK and reducing JNK activation in stimulated cells ([Figure 10](#fig10){ref-type="fig"}).

While the mechanistic details remain to be fully elucidated, the relevance of the imbalance in MAPK signaling for the development of the atopic dermatitis-like disease in Δ/Δep2 animals was shown in vivo in two complementary ways: 1) by preventing disease onset with the specific peptide inhibitor D-JNKI1; and 2) by inducing disease in healthy RAF1Δep animals with a MEK inhibitor ([Figure 10](#fig10){ref-type="fig"}). The second set of experiments also clearly shows that the function of BRAF and RAF1 in the epidermis is not redundant. Finally, the combined RAF knockout and inhibitor data help explain why in patients the cutaneous toxicity of RAF inhibitors, which increase ERK activation, is mostly related to hyperproliferation ([@bib2]), while inhibitors of ERK activation promote the onset or exacerbate the course of cutaneous inflammatory reactions involving stress kinase activation ([@bib12]).

Materials and methods {#s4}
=====================

Animal studies and inhibitor treatment {#s4-1}
--------------------------------------

All strains were maintained on a Sv/129 background. *Krt5-CreBraf ^f/f^;Raf1^f/f^* mice were generated for this study by mating *Krt5-Cre;Braf^f/f^:: Krt5-Cre;Raf1^f/f^*animals. These strains, the *Krt5-CreER(TX);Braf ^f/f^;Raf1^f/f^* mice as well as their genotyping and the tamoxifen-induced deletion of the *RAF* alleles have been previously described ([@bib34]; [@bib20]). Inducible RAF deletion was performed at the age of three weeks.

*Krt5-CreBraf ^f/f^;Raf1^f/f^* were mated with MyD88 ([@bib1]), TNF ([@bib37]), and caspase 1/11 ([@bib55]) knockout mice, all maintained on a C57BL/6 background, to test the contribution of the respective signaling pathways to the *Krt5-CreBraf ^f/f^;Raf1^f/f^* phenotype.

In selected experiments, the MEK inhibitor GSK1120212 (trametinib, Selleckchem, Germany) was applied daily by gavage for 32 days ([@bib17]). The peptide inhibitor D-JNKI1 was synthesized at the Istituto di Ricerche Farmacologiche \'Mario Negri\' (Milano, Italy), as previously described ([@bib6]). Ten days old animals were injected once i.p. (22 mg/kg) with D-JNKI1 or TAT peptide control ((D-Pro1,2) retro-(D-HIV-TAT (aa 48-57), Enzo Life Sciences, NY, USA, BML-El384-0001). Animal experiments were authorized by the Austrian Ministry of Science, Research and Economy.

Histology and immunohistochemistry {#s4-2}
----------------------------------

H&E staining, TUNEL, BrdU incorporation and immunohistochemistry were carried out as described ([@bib21]) on paraffin or cryostat sections. The following antibodies were used: β1 Tryptase (AF1937) and ICAM1 (AF796) from R&D Systems (Minneapolis, MN); CD11c (14--0114) and MHC II (14--5321) from Affymetrix eBioscience (Santa Clara, CA); K6 (905701), K5 (905501), K10 (905401) and Involucrin (924401) from BioLegend (San Diego, CA); F4/80 (AbDSerotec, UK, MCAP497); CD4 (550280) and CD8 (550281) from BD Biosciences (San Jose, CA); Filaggrin (ab24584), pRSK (ab32413) and pJNK (ab4821) from Abcam (UK); pJUN (9164) and pERK (4376) from Cell Signaling Technology (Danvers, MA). Granulocytes were visualized using the Naphthol AS-D Chloroacetate (specific esterase) kit (Sigma, 91C-1KT) according to the manufacturer\'s instruction. Toluidine blue staining for mast cells was carried out as described ([@bib42]). Histology images were acquired with a ZEISS microscope Imager M1 (20x/0.5 or 10x/0.3 Plan-NeoFluar objectives) equipped with ZEISS AxioCamMRc5. Data were analyzed with ZEISS Axiovision Release 4.8.1 software (Carl Zeiss, Germany). Fluorescent images were acquired with ZEISS Axioplan2 microscope (40x objective, Zeiss Plan -- NEOFLUAR; Num: ap. 1.3) equipped with Spot Pursuit Camera (Visitron Systems, Germany) and analyzed with VisiView software (Visitron Systems).

Blood analysis and FACS {#s4-3}
-----------------------

Peripheral blood cell counts were acquired using V-Sight (Menarini Diagnostics, Italy). Spleen and lymph node cells were stained with antibodies against CD11c (550261), CD4 (553051), MHC II (557000), CD69 (557392), CD80 (553768), CD8 (553032), B220 (553090), Mac1 (553310) and Gr1 (553128) all from BD Bioscience and analyzed by FACSCalibur (BD Bioscience) and FlowJo V10 software (Ashland, OR).

FlowCytomix analyte assay and ELISA {#s4-4}
-----------------------------------

Cytokines and chemokines were detected in cell supernatants, serum samples and epidermal tissue lysates using the Affymetrix eBioscience bead-based multiplex immunoassay. Data were analyzed with FlowCytomix Pro2.4 software. GCSF (R&D Systems, DY414), TSLP (R&D Systems, DY555) and IgEs (Bethyl Laboratories, E90-115) in serum samples were detected by ELISA according to the manufacturer\'s protocol.

Barrier function assays {#s4-5}
-----------------------

Water loss assay and toluidine blue dye staining of embryos were carried out as described ([@bib60]).

Cell culture {#s4-6}
------------

HaCaT cells obtained from the DKFZ and mouse keratinocytes were maintained as described ([@bib17]). BRAF (L-003460-00), MLK3 (L-003577-00) and RAF1 (L-003601-00) were silenced using ON-TARGETplus SMARTpool siRNAs (Thermo Fisher Scientific, Waltham, MA). Nontargeting pool (D-001810-10-20) was used as control. In accordance with the supplier\'s protocol, 5×10^5^ cells were transfected with 25 nM of the previously mentioned oligos. Cells were treated with EGF (2 ng/ml, R&D Systems, 2028-EG) and/or with TNFα (2.5 ng/ml, Millipore, Billerica, MA, 654245) and IL1β (2.5 ng/ml, R&D Systems, 401-ML/CF) as indicated. For cytokine/chemokine assays supernatants were collected 24 hr later. In selected experiments, cells were pretreated for 1 hr with medium containing DMSO (for trametinib) or TAT peptide only (for D-JNKI1) or with the following inhibitors: D-JNKI1 (2µM) or trametinib (5µM).

Lentiviral vectors, cloning and transduction procedure {#s4-7}
------------------------------------------------------

Two independent shRNAs against mouse MLK3 (shRNA1, binding site 2266--2285 and shRNA2, binding site 2383--2402) were designed as 97-bp oligomers containing a 20bp targeting sequence embedded in a shRNAmir stem, amplified and cloned into Xho and EcoRI sites of the miRE lentiviral recipient vector pRRL.SFFV.GFP.miRE.PGK.Puro (SGEP) ([@bib23]). The SGEP plasmid containing Renilla shRNA served as a control. Lentiviral vectors were transfected in 293T cells. Viral supernatants were collected after 24 and 48 hr and passed through a 0.45-μm filter (Sarstedt, Germany). Each fresh viral supernatant was used for primary keratinocyte spinfection (1500 *g*, 30 min). Primary keratinocyte cultures were harvested 72 hr after first transduction.

Immunoblotting {#s4-8}
--------------

Cell and epidermal lysates prepared as previously described ([@bib17]) were immunoblotted using the following primary antibodies (1:1000): TUBA (T9206,) from Sigma; pERK1/2 (9101), ERK1/2 (9102), JNK1/2 (9258), pJNK 1/2 (9251), pJUN (9164), pMAPKAPK2 (3041), pp38 (9211), p38 (9212) and ICAM1 (4915) from Cell Signaling Technology; ACTB (sc-1616), 14-3-3 (sc-1657), BRAF (sc-5284), RAF1 (sc-133) and MLK3 (sc-166639 and sc-536) from Santa Cruz Biotechnology (Dallas, TX); CDH1 (610181) from BD Biosciences; OCLN (ab31721), pRSK (ab32413), TSLP (ab188766) and DUSP10 (ab140123) from Abcam; GAPDH (ABS16) and DUSP1 (07--535) from Millipore; ICAM1 (AF796, R&D Systems) and CLDN1 (374900, Invitrogen, Karlsbad, CA).

Quantitative PCR {#s4-9}
----------------

RNA was isolated using Nucleospin RNA II kit (Macherey-Nagel, Germany). cDNA was prepared using Oligo(dT)~18~ primer, dNTPs, and RevertAidReverse Transcriptase (Thermo Fisher Scientific). qPCR was performed using Go Taq qPCR Master mix (A6002, Promega, Madison, WI). Relative expression was calculated by the ΔΔCT method using *ACTB* as housekeeping gene. Human *CCL2* primers used: for 5\`-CAGCCAGATGCAATCAATGC-3´ and rev 5´-GCACTGAGATCTTCCTATTGGTGAA-3´, human *ACTB* for 5\`-AGAGCTACGAGCTGCCTGAC-3´ and rev 5´-AGCACTGTGTTGGCGTACAG-3´. Mouse *Ccl2* primers used: for 5\`-CCCAATGAGTAGGCTGGAGA-3´ and 5\`-AAAATGGATCCACACCTTGC-3´; mouse *Tslp* for 5\`-CGACAGCATGGTTCTTCTCA-3´ and 5\`-CGATTTGCTCGAACTTAGCC-3´, mouse *ActB* for 5\`-CCTCTATGCCAACACAGTGC-3´ and 5\`-GTACTCCTGCTTGCTGATCC-3´.

Statistical analysis {#s4-10}
--------------------

Histological samples from at least three animals per condition and genotype were analyzed by counting or measuring at least 3--5 microscopic field/section and analyzed by ImageJ software. Values are expressed as mean (±SEM). The number of biological replicates and, where applicable, technical replicates are indicated in the figure legends. p values were calculated using the two-tailed Student\'s t test, hetero- or homoskedastic as determined by a previous F-test of equality of variances or, when indicated, by two-way analysis of variance (ANOVA) test. A p value ≤ 0.05 is considered statistically significant.
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your work entitled \"Epidermal RAF prevents allergic skin disease\" for consideration by *eLife*. Your article has been favorably evaluated by Tony Hunter (Senior editor) and four reviewers, one of whom is a member of our Board of Reviewing Editors.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted a list of experiments and changes that we feel must be completed before this work could be published in *eLife*. At this point, it would help us to have a response from you concerning the list of requirements and the time it would take to complete these task before we make a final recommendation.

Summary:

The manuscript addresses the role of the RAF kinases BRAF and RAF1 in keratinocytes. Mice with combined loss of expression of these kinases in the epidermis exhibit skin defects similar to the human disease, atopic dermatitis (AD). There is local and systemic inflammation, including increased production of chemokines and TH2-type cytokines. The authors show that BRAF is required for ERK activation and that RAF1 suppresses the activation of the stress-activated MAP kinases JNK and p38. Inhibition of JNK in mice prevents the skin defects while inhibition of MEK in mice lacking epidermal RAF1 promotes these.

The authors conclude that RAF enzymes play a key role in the pathogenesis of the atopic dermatitis-like disease in mice and suggest that this may represent a relevant model for studying the disease. Overall the study is interesting. It builds on previous work addressing the complex interplay between the RAF enzymes and the observations that inhibitors targeting RAF can result in inflammatory skin conditions.

Essential revisions:

1\) TSLP is a key cytokine for AD-like disease, thus an increase in TSLP levels is very relevant for the conclusions of this study. However, TSLP staining in the epidermis does not look specific, as it should be localized to the cytoplasm, not to the nucleus. The authors should determine the levels of TSLP by RNA and protein (WB or ELISA) in epidermal extracts in all Figures.

2\) It is well accepted that IL-4/IL-13 cytokines play important roles in the development of AD. It is necessary to include analyses of both cytokines in all experiments.

3\) The IHC analysis is difficult to interpret; some examples include [Figure 3A](#fig3){ref-type="fig"} where the panels are too small; Figure 6---figure supplement 1 where the changes in staining between F/F2 and ∆/∆ep2 are unclear; in [Figure 8B](#fig8){ref-type="fig"}: please use the same magnification that is used for TSLP staining in all panels to make staining more visible; and in regards to ICAM staining use, a better example that clearly shows the epidermis is needed. In general, the quality of all IHC images should be improved and quantifications should be included.

4\) The data on MLK3 expression in HaCat cells are not convincing. Is MLK3 activated by loss of Raf1/Braf? JNK inhibition in KD2 cells in [Figure 9D](#fig9){ref-type="fig"} is not clear either, and thus these results should be repeated in ∆/∆ep2 keratinocytes in vitro.

5\) There is a large body of evidence presented in the manuscript as data not shown that relates to the investigation of increased JNK activation, such as mating the ∆/∆ep2 mice to MyD88, TNFα and caspase 1/11 knock-out mice. These data should be included in the paper, as these results are relevant to the conclusions of the manuscript.

6\) The use of SP600125 is not recommended because it is a relatively non-selective kinase inhibitor. Any experiment where SP600125 was used should be replaced with a more selective inhibitor.

7\) The RNAi studies are poorly designed -- phenotypes should be confirmed with two independent single oligonucleotides and rescued by expression of an RNAi-resistant cDNA.

8\) The authors show that BRAF/RAF1 deletion causes an \"inside out\" barrier defect ([Figure 4](#fig4){ref-type="fig"}). Comparing mice with combined BRAF/RAF1 deletion, with mice presenting single deletion for BRAF or RAF1, would be important. Some studies have shown that RAF1 is implicated in disrupting tight junctions (Oncogene. 2007 26(8):1222-30 PMID: 16924233; J Cell Biol. 2000 148(4):791-800.PMID: 10684259).

9\) The transient barrier defect conclusion in E18.5 embryos is unclear. At the end of the subsection "Lack of epidermal BRAF and RAF1 causes transient inside-out barrier defects" it is proposed that this defect affects the progression of the disease. This is partly based on the fact that deletion of Braf/Raf1 at 3 weeks produces a more modest phenotype. This may be one possible explanation. The milder phenotype may be a reflection of less robust gene deletion in the K5CreER(TX) mice. An immunoblot of epidermal lysates for BRAF and RAF1 should be included in [Figure 5A](#fig5){ref-type="fig"}.

10\) [Figure 6](#fig6){ref-type="fig"}: First, there appears to be specific activation of one ERK isoform (which one?) based on the pERK immunoblot in [Figure 6A](#fig6){ref-type="fig"}, whilst in [Figure 6C](#fig6){ref-type="fig"} both isoforms are phosphorylated. Second, [Figure 6B](#fig6){ref-type="fig"} -- significance value for IL-13 missing. Third, [Figure 6D](#fig6){ref-type="fig"} -- what is the explanation for why D-JNKi specifically suppresses CCL2 and CCL7 levels in the Δ/Δep2 mice, while the JNK/p38 inhibitors reduce levels in both F/F2 and knock-out mice?

11\) [Figure 7A](#fig7){ref-type="fig"}: D-JNKi appears to suppress pERK in F/F2 epidermis to similar levels as found in Δ/Δep2. Is there an explanation for this?

12\) Overall the outline of the paper is not very logical and it should be improved for clarity. For example, the analysis of the inflammation markers is often inconsistent, and the cytokines/chemokines shown in [Figure 1F](#fig1){ref-type="fig"} should also be shown in the subsequent figures such as [Figure 2D](#fig2){ref-type="fig"}.
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Author response

*Essential revisions:*

1\) TSLP is a key cytokine for AD-like disease, thus an increase in TSLP levels is very relevant for the conclusions of this study. However, TSLP staining in the epidermis does not look specific, as it should be localized to the cytoplasm, not to the nucleus. The authors should determine the levels of TSLP by RNA and protein (WB or ELISA) in epidermal extracts in all Figures.

The level of TSLP determined by immunoblotting have been found elevated in adult animals ([Figure 1F](#fig1){ref-type="fig"}), and in 3 weeks old mice ([Figure 3B](#fig3){ref-type="fig"}); in addition, TSLP levels are decreased in D-JNKI1-treated ∆/∆ep2 mice ([Figure 8A](#fig8){ref-type="fig"}) and increased in RAF1∆/∆ep mice treated with MEKi ([Figure 7C](#fig7){ref-type="fig"}). TSLP amounts, determined by ELISA, are significantly increased in the supernatant of primary Δ/Δep2 keratinocytes; treatment with a D-JNKI1 abolishes this increase ([Figure 9B and D](#fig9){ref-type="fig"}); Tslp mRNA levels are also increased in Δ/Δep2 keratinocytes; this increase is abolished by MLK3 silencing ([Figure 9F](#fig9){ref-type="fig"}). Collectively, the data show that TSLP is elevated in a JNK pathway-dependent manner in Δ/Δep2 tissues and cells.

2\) It is well accepted that IL-4/IL-13 cytokines play important roles in the development of AD. It is necessary to include analyses of both cytokines in all experiments.

These data were already included in the manuscript, either in the main Figures (original 1F, adult mice -- now [Figure 1G](#fig1){ref-type="fig"}; [Figure 3B](#fig3){ref-type="fig"}, 3-weeks old mice; original [Figure 7C](#fig7){ref-type="fig"}, and [Figure 7---figure supplement 1A](#fig7s1){ref-type="fig"},D-JNKI1 -- now [Figure 8C](#fig8){ref-type="fig"} and [Figure 8---figure supplement 1A](#fig8s1){ref-type="fig"}; original [Figure 8](#fig8){ref-type="fig"} and [Figure 8---figure supplement 1](#fig8s1){ref-type="fig"}, trametinib -- now [Figure 7C](#fig7){ref-type="fig"} and [Figure 7---figure supplement 1](#fig7s1){ref-type="fig"}; original [Figure 6B](#fig6){ref-type="fig"} -- now [Figure 9B](#fig9){ref-type="fig"}, keratinocytes). IL-4 was not detected, this is stated in the first paragraph of the subsection "Interfering with the JNK pathway decreases the production of proinflammatory molecules in primary Δ/Δep2 keratinocytes and RAF knockdown HaCat cells"..

3\) The IHC analysis is difficult to interpret; some examples include [Figure 3A](#fig3){ref-type="fig"} where the panels are too small; Figure 6---figure supplement 1 where the changes in staining between F/F2 and ∆/∆ep2 are unclear; in [Figure 8B](#fig8){ref-type="fig"}: please use the same magnification that is used for TSLP staining in all panels to make staining more visible; and in regards to ICAM staining use, a better example that clearly shows the epidermis is needed. In general, the quality of all IHC images should be improved and quantifications should be included.

We used low magnification to show a larger portion of the epidermis; however, we agree with the reviewers that some of the immunostainings are less clear in this magnification. The revised manuscript includes higher magnifications in [Figure 3A](#fig3){ref-type="fig"}, [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}, Figure 6---figure supplement 1 (original manuscript; now [Figure 6A](#fig6){ref-type="fig"}); in [Figure 8B](#fig8){ref-type="fig"} (now [Figure 7B](#fig7){ref-type="fig"}), the same magnification originally used for the TSLP panel has been used for K6 and ICAM1; however, the original lower magnification is still shown for the panels showing changes in the dermis, i.e.: H&E, β1-tryptase, and toluidine blue. Quantifications of the IHC analysis are shown wherever they are possible.

4\) The data on MLK3 expression in HaCat cells are not convincing. Is MLK3 activated by loss of Raf1/Braf? JNK inhibition in KD2 cells in [Figure 9D](#fig9){ref-type="fig"} is not clear either, and thus these results should be repeated in ∆/∆ep2 keratinocytes in vitro.

We have succeeded in performing this experiment (JNK inhibition by MLK3 silencing) in ∆/∆ep2 keratinocytes, even if knockdown experiments in primary cells are notoriously difficult. The lentiviral vectors used to knockdown MLK3 in keratinocytes were constructed by Joanna Nowacka in the lab. The authors' list has been revised to reflect her contribution. The new experiment is shown in revised [Figure 9E--F](#fig9){ref-type="fig"}, while the original experiment in HaCat cells is now shown in [Figure 9---figure supplement 1](#fig9s1){ref-type="fig"}). Concerning MLK3 activation, we have now tried several different phosphospecific antibodies against the autophosphorylation sites, all of which gave a very high background but no reliable signal. However, the lack of JNK activation in unstimulated Δ/Δep2 keratinocytes suggests a cross-talk at the level of BRAF/RAF1 and MLK3 rather than direct MLK3 activation by BRAF/RAF1 ablation. A sentence to this effect has been added to the Discussion (subsection "An imbalance in MAPK signaling underlies skin inflammation in Δ/Δep2 mice", second paragraph).

5\) There is a large body of evidence presented in the manuscript as data not shown that relates to the investigation of increased JNK activation, such as mating the ∆/∆ep2 mice to MyD88, TNFα and caspase 1/11 knock-out mice. These data should be included in the paper, as these results are relevant to the conclusions of the manuscript.

The revised manuscript includes representative pictures of the animals and of their lymphoid organs ([Figure 8---figure supplement 2](#fig8s2){ref-type="fig"}) as well as information on the number of animals monitored (Legend to [Figure 8---figure supplement 2](#fig8s2){ref-type="fig"}) and on the time of disease onset. The paragraph read as follows:

"None of these knockouts altered the progression (onset around 2 months of age) or severity of the Δ/Δep2 skin disease ([Figure 8---figure supplement 2](#fig8s2){ref-type="fig"}). The Myd88 KO, however, reduced the splenomegaly observed in the Δ/Δep2 mice. This specific phenotype is due to an increase in Mac1+/Gr1+ splenocytes ([Figure 2B](#fig2){ref-type="fig"}), and its selective rescue in the compound Δ/Δep2;MyD88 KO animals is likely due to the crucial role of MyD88 in the generation of these cells (Arora et al., 2010; Delano et al., 2007)."

*6) The use of SP600125 is not recommended because it is a relatively non-selective kinase inhibitor. Any experiment where SP600125 was used should be replaced with a more selective inhibitor.*

All experiments involving SP600125 have been replaced with experiments in which JNK activation was inhibited by D-JNKI1. In addition, the experiment in revised [Figure 9C](#fig9){ref-type="fig"} now clearly shows that D-JNKI1 reduces ICAM1 expression in ∆/∆ep2 primary keratinocytes.

7\) The RNAi studies are poorly designed -- phenotypes should be confirmed with two independent single oligonucleotides and rescued by expression of an RNAi-resistant cDNA.

The RNAi studies involving knockdown of Raf1 and BRaf are backed up by all the experiments performed in knockout mice and cells, making off-target effects more than unlikely. Therefore, we have attempted to perform the requested experiments/controls only for MLK3 knockdown in Δ/Δep2 keratinocytes (see also response to point 4). Knockdown/re-expression experiments in primary mouse keratinocytes are notoriously difficult; we have succeeded in targeting MLK3 with two separate hairpins encoded by a lentiviral vector, but the reconstitution experiments using a single vector expressing both the hairpin and WT or shRNA-resistant MLK3 have failed because the infection efficiency with these large constructs went from 60-90% to less than 20%. This is a problem because keratinocytes cannot be FACS-sorted -- they will not reattach and in fact will die after sorting. Irrespective of this, we now show that MLK3 knockdown by two distinct shRNAs in primary keratinocytes (revised [Figure 9E--F](#fig9){ref-type="fig"} and Figure legend to [Figure 9](#fig9){ref-type="fig"}; discussed in the last paragraph of the subsection "Interfering with the JNK pathway decreases the production of proinflammatory molecules in primary Δ/Δep2 keratinocytes and RAF knockdown HaCat cells") has the same effect as MLK3 knockdown by a pool of siRNAs targeting distinct sites in HaCat cells ([Figure 9---figure supplement 1](#fig9s1){ref-type="fig"} of the revised version). We are therefore confident that the effects of MLK3 silencing are specific.

8\) The authors show that BRAF/RAF1 deletion causes an \"inside out\" barrier defect ([Figure 4](#fig4){ref-type="fig"}). Comparing mice with combined BRAF/RAF1 deletion, with mice presenting single deletion for BRAF or RAF1, would be important. Some studies have shown that RAF1 is implicated in disrupting tight junctions (Oncogene. 2007 26(8):1222-30 PMID: 16924233; J Cell Biol. 2000 148(4):791-800.PMID: 10684259).

This experiment has been included in the revised manuscript ([Figure 4---figure supplement 1C--D](#fig4s1){ref-type="fig"}; discussed in the first paragraph of the subsection "Lack of epidermal BRAF and RAF1 causes transient inside-out barrier defects"). The figure shows that neither single knockout shows inside-out barrier defects or reduced tight junction proteins expression.

9\) The transient barrier defect conclusion in E18.5 embryos is unclear. At the end of the subsection "Lack of epidermal BRAF and RAF1 causes transient inside-out barrier defects" it is proposed that this defect affects the progression of the disease. This is partly based on the fact that deletion of Braf/Raf1 at 3 weeks produces a more modest phenotype. This may be one possible explanation. The milder phenotype may be a reflection of less robust gene deletion in the K5CreER(TX) mice. An immunoblot of epidermal lysates for BRAF and RAF1 should be included in [Figure 5A](#fig5){ref-type="fig"}.

This experiment has been included in [Figure 5A](#fig5){ref-type="fig"}. As described in the second paragraph of the subsection "Lack of epidermal BRAF and RAF1 causes transient inside-out barrier defects" and shows nearly complete deletion of both proteins in epidermal lysates.

10\) [Figure 6](#fig6){ref-type="fig"}: First, there appears to be specific activation of one ERK isoform (which one?) based on the pERK immunoblot in [Figure 6A](#fig6){ref-type="fig"}, whilst in [Figure 6C](#fig6){ref-type="fig"} both isoforms are phosphorylated. Second, [Figure 6B](#fig6){ref-type="fig"} -- significance value for IL-13 missing. Third, [Figure 6D](#fig6){ref-type="fig"} -- what is the explanation for why D-JNKi specifically suppresses CCL2 and CCL7 levels in the Δ/Δep2 mice, while the JNK/p38 inhibitors reduce levels in both F/F2 and knock-out mice?

In the revised version of the manuscript, [Figure 6C](#fig6){ref-type="fig"} (now 9C) has been replaced by a new figure showing the effect of the specific JNK inhibitor D-JNKI1. We agree with the reviewer, however, that there is some preference for the phosphorylation of one isoform, and this is ERK2. This can also be observed in epidermal lysates throughout the paper and in HaCat cells. The reason for this preference is not known, but unequal phosphorylation of ERK isoforms has been frequently observed in many different tissues and cells. [Figure 6B](#fig6){ref-type="fig"} (now 9B), we stand corrected; this value has been inserted in the revised Figure. [Figure 6D](#fig6){ref-type="fig"} (now removed), the explanation is likely that SP600125+SB203580 have a stronger impact and more off target effects than the specific D-JNKI1. In fact we have been requested to remove the experiments in which SP600125 was used for exactly this reason.

11\) [Figure 7A](#fig7){ref-type="fig"}: D-JNKi appears to suppress pERK in F/F2 epidermis to similar levels as found in Δ/Δep2. Is there an explanation for this?

There is no obvious or easy explanation for this result; however, it should be noted that gradual differences in intensity observed in IHC may be difficult to interpret. We have therefore performed immunoblot analysis of epidermal lysates, which has given us a more quantitative measure of the differences observed in [Figure 7A](#fig7){ref-type="fig"} ([Figure 8A](#fig8){ref-type="fig"} in the revised version) and does not show a significant reduction in pERK or in the downstream target pRSK in F/F2 epidermal lysates.

12\) Overall the outline of the paper is not very logical and it should be improved for clarity. For example, the analysis of the inflammation markers is often inconsistent, and the cytokines/chemokines shown in [Figure 1F](#fig1){ref-type="fig"} should also be shown in the subsequent figures such as [Figure 2D](#fig2){ref-type="fig"}.

We have done our best to improve the manuscript's clarity, describing all the in vivo studies first and moving the experiments with cultured cells, now restricted to keratinocytes, to the end of the results. We have also inverted the order of [Figures 7](#fig7){ref-type="fig"} and [8](#fig8){ref-type="fig"}; in the current version of the manuscript, the in vivo experiments using D-JNKI1 directly precede the experiments in primary keratinocytes, which also explore the impact of the JNK pathway on the phenotype in culture. Concerning inflammation markers, we have added K6 as an inflammation marker in addition to ICAM1 in all experiments. The cytokines/chemokines shown in [Figure 1G](#fig1){ref-type="fig"} are shown for each experiment, but in the Figure supplements rather than in the main Figures, which are already extremely crowded.
